Centessa Pharmaceuticals (NASDAQ:CNTA) Posts Earnings Results, Beats Estimates By $0.04 EPS

Centessa Pharmaceuticals (NASDAQ:CNTA) posted its quarterly earnings data on Monday. The company reported ($0.34) EPS for the quarter, beating the consensus estimate of ($0.38) by $0.04, Zacks reports.

Centessa Pharmaceuticals Trading Up 5.6 %

Shares of CNTA opened at $16.63 on Tuesday. Centessa Pharmaceuticals has a 1-year low of $7.75 and a 1-year high of $19.09. The company has a debt-to-equity ratio of 0.15, a current ratio of 21.52 and a quick ratio of 21.52. The firm has a 50 day simple moving average of $16.49 and a 200-day simple moving average of $16.42. The stock has a market cap of $2.19 billion, a price-to-earnings ratio of -10.87 and a beta of 1.54.

Analysts Set New Price Targets

CNTA has been the subject of several recent research reports. TD Cowen began coverage on Centessa Pharmaceuticals in a report on Tuesday, January 7th. They set a “buy” rating for the company. Guggenheim reiterated a “buy” rating on shares of Centessa Pharmaceuticals in a research note on Monday, February 10th. Finally, Morgan Stanley reaffirmed an “overweight” rating and issued a $27.00 price objective on shares of Centessa Pharmaceuticals in a report on Friday, March 7th. Seven investment analysts have rated the stock with a buy rating, According to MarketBeat, the stock presently has a consensus rating of “Buy” and a consensus target price of $26.00.

Insider Buying and Selling at Centessa Pharmaceuticals

In other Centessa Pharmaceuticals news, insider Karen M. Anderson sold 30,526 shares of the stock in a transaction on Friday, February 7th. The stock was sold at an average price of $19.03, for a total transaction of $580,909.78. Following the transaction, the insider now owns 54,322 shares of the company’s stock, valued at $1,033,747.66. This represents a 35.98 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this link. Also, insider Gregory M. Weinhoff sold 10,000 shares of Centessa Pharmaceuticals stock in a transaction on Thursday, December 26th. The shares were sold at an average price of $17.04, for a total value of $170,400.00. Following the completion of the sale, the insider now directly owns 183,266 shares of the company’s stock, valued at approximately $3,122,852.64. This represents a 5.17 % decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 260,168 shares of company stock worth $4,316,568. 11.59% of the stock is owned by insiders.

Centessa Pharmaceuticals Company Profile

Centessa Pharmaceuticals plc, a clinical-stage pharmaceutical company, discovers, develops, and delivers medicines for patients. Its products pipeline includes SerpinPC, an activated protein C inhibitor for the treatment of hemophilia A and B; and ORX750, an orally administered OX2R agonist for the treatment of narcolepsy and other sleep disorders.